Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 241

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications

Hou, Hsin-An, Kuo, Yuan-Yeh, Liu, Chieh-Yu, Chou, Wen-Chien, Lee, Ming Cheng, Chen, Chien-Yuan, Lin, Liang-In, Tseng, Mei-Hsuan, Huang, Chi-Fei, Chiang, Ying-Chieh, Lee, Fen-Yu, Liu, Ming-Chih, Liu, Chia-Wen, Tang, Jih-Luh, Yao, Ming, Huang, Shang-Yi, Ko, Bor-Sheng, Hsu, Szu-Chun, Wu, Shang-Ju, Tsay, Woei, Chen, Yao-Chang, Tien, Hwei-Fang · 2012 · Blood

Abstract

DNMT3A mutations are associated with poor prognosis in acute myeloid leukemia (AML), but the stability of this mutation during the clinical course remains unclear. In the present study of 500 patients with de novo AML, DNMT3A mutations were identified in 14% of total patients and in 22.9% of AML patients with normal karyotype. DNMT3A mutations were positively associated with older age, higher WBC and platelet counts, intermediate-risk and normal cytogenetics, FLT3 internal tandem duplication, and NPM1, PTPN11, and IDH2 mutations, but were negatively associated with CEBPA mutations. Multivariate analysis demonstrated that the DNMT3A mutation was an independent poor prognostic factor for overall survival and relapse-free survival in total patients and also in normokaryotype group. A scoring system incorporating the DNMT3A mutation and 8 other prognostic factors, including age, WBC count, cytogenetics, and gene mutations, into survival analysis was very useful in stratifying AML patients into different prognostic groups (P < .001). Sequential study of 138 patients during the clinical course showed that DNMT3A mutations were stable during AML evolution. In conclusion, DNMT3A mutations are associated with distinct clinical and biologic features and poor prognosis in de novo AML patients. Furthermore, the DNMT3A mutation may be a potential biomarker for monitoring of minimal residual disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-07-369934

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 241

Metadata

Authors
Hou, H.-A., Kuo, Y.-Y., Liu, C.-Y., Chou, W.-C., Lee, M. C., Chen, C.-Y., Lin, L.-I., Tseng, M.-H., Huang, C.-F., Chiang, Y.-C., Lee, F.-Y., Liu, M.-C., Liu, C.-W., Tang, J.-L., Yao, M., Huang, S.-Y., Ko, B.-S., Hsu, S.-C., Wu, S.-J., Tsay, W., Chen, Y.-C., & Tien, H.-F.
Venue
Blood
Published
2012-01-12
Volume
119
Issue
2
Pages
559-568
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2046829201
Cited by
241
References
2
FWCI
13.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. https://app.cochat.ai/papers/10.1182/blood-2011-07-369934
The paper
Hou, H.-A., Kuo, Y.-Y., Liu, C.-Y., Chou, W.-C., Lee, M. C., Chen, C.-Y., Lin, L.-I., Tseng, M.-H., Huang, C.-F., Chiang, Y.-C., Lee, F.-Y., Liu, M.-C., Liu, C.-W., Tang, J.-L., Yao, M., Huang, S.-Y., Ko, B.-S., Hsu, S.-C., Wu, S.-J., . . . Tien, H.-F. (2012). DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood. https://doi.org/10.1182/blood-2011-07-369934

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.